Biotech · Private company · Doylestown, PA, US
Nous Biosciences Inc
Track this companyFree. Adds Nous Biosciences Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Combination of formulated dolcanatide, a guanylate cyclase-C agonist, with formulated atiprimod, a JAK-STAT inhibitor, for treatment of murine colitis.Fiscal year 2025 · $358KNIH RePORTER 1R43DK141298-01A1 · fetched Nov 12, 2026
- Microsphere-based formulation of dolcanatide to prevent colon carcinogenesisFiscal year 2025 · $90.7KNIH RePORTER 5R43CA291267-02 · fetched Nov 12, 2026
- Microsphere-based formulation of dolcanatide to prevent colon carcinogenesisFiscal year 2024 · $308.7KNIH RePORTER 1R43CA291267-01 · fetched Nov 12, 2026